Comparative evaluation of Latanoprostene Bunod, Timolol Maleate, and latanoprost Ophthalmic Solutions to assess their safety and efficacy in lowering intraocular pressure for the management of Open-Angle Glaucoma

Wang, Yulong; Liao, Yue; Nie, Xin

doi:10.6061/clinics/2020/e1874

Cited by 10 publications

(5 citation statements)

References 19 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LBN was also effective in patients with earlier disease. The findings of this study contrast with those of a study presented at ARVO 2019, which reported that LBN treated patients had a nonsignificant IOP reduction of 0.67 mm Hg 19. The majority of the patients in both studies had advanced glaucoma and the mean number of medications was similar (3.0 vs. 3.2), so the difference in efficacy is not easily explained.…”

Section: Discussioncontrasting

confidence: 99%

“…As all patients were switched to LBN from another PGA or from latanoprost/netarsudil FDC, these results suggest that LBN may be more effective than PGAs that do not include a nitric oxide-donating moiety. This finding corroborates those of a recent meta-analysis indicating that LBN was significantly superior to unoprostone and nonsignificantly superior to latanoprost and travoprost over 3 months of treatment,19 along with a retrospective study in China showing that patients on LBN had greater reductions in IOP than patients on latanoprost, also over 3 months 20. In the present study, IOP reduction on LBN was stable throughout follow-up, similar to what was reported in the phase 3 clinical trials,14 and remained clinically significant in the 30 patients who were treated with LBN for >6 months.…”

Section: Discussionsupporting

confidence: 91%

“…The findings of this study contrast with those of a study presented at ARVO 2019, which reported that LBN treated patients had a nonsignificant IOP reduction of 0.67 mm Hg. 19 The majority of the patients in both studies had advanced glaucoma and the mean number of medications was similar (3.0 vs. 3.2), so the difference in efficacy is not easily explained. The present study's data for LBN's real-world efficacy in patients on multiple glaucoma medications, often with surgical histories, complement those of the Okeke study, which showed that LBN was effective specifically in treatment-naive eyes with a new glaucoma diagnosis.…”

Section: Discussionmentioning

confidence: 89%

See 2 more Smart Citations

Two-Year Experience With Latanoprostene Bunod in Clinical Practice

Radell

Sharma

Auyeung

et al. 2021

Journal of Glaucoma

View full text Add to dashboard Cite

We retrospectively reviewed records of patients prescribed latanoprostene bunod 0.024% (LBN) to assess its efficacy and safety in a real-world clinical setting. LBN was efficacious in lowering intraocular pressure (IOP) and had a favorable safety profile. Purpose:The aim of this study was to evaluate the usage of LBN, the first topical nitric oxide-donating prostaglandin analog (PGA) for reducing IOP, in clinical practice.Patients and Methods: Retrospective review identified patients prescribed LBN by 5 glaucoma specialists at an academic center from January 2018 to November 2019. Fifty-six patients (102 eyes) met inclusion criteria of an IOP measured at the visit LBN was prescribed and at 2 visits ≥ 7 days after beginning treatment, with no surgeries, lasers or medication changes during follow-up. Main outcome measures were IOP, number of ocular medications, and adverse effects.Results: IOP (mean ± SD, mm Hg) at the visit LBN was prescribed was 16.2 ± 4.3 on 3.2 ± 1.5 glaucoma medications. IOP at most recent visit was 13.7 ± 3.8 on 3.2 ± 1.6 medications. Mean IOP reduction was 2.1 ± 3.5 (P < 0.0001) at first follow-up, after 38.7 ± 36.5 days, and 2.5 ± 3.3 (P < 0.0001) at last follow-up, after 235.9 ± 160.8 days. Pressure decreased ≥ 2 mm Hg in 60%, ≥ 3 mm Hg in 46%, and ≥ 4 mm Hg in 34% of eyes. All patients received LBN as replacement for a PGA or latanoprost/netarsudil fixed-dose combination. Forty-three patients remained on LBN throughout the follow-up period. Seven were discontinued for insufficient pressure control, 4 for adverse effects including pain and itching, and 2 for financial reasons. Conclusions:In 2 years of clinical use of LBN, patients exhibited IOP reductions that were statistically significant overall and clinically meaningful in 60% of patients. LBN was well-tolerated and may be more efficacious than traditional PGAs.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 89%

See 1 more Smart Citation

Two-Year Experience With Latanoprostene Bunod in Clinical Practice

Radell

Sharma

Auyeung

et al. 2021

Journal of Glaucoma

View full text Add to dashboard Cite

show abstract

“…Therefore, improving optic nerve blood supply is also of great significance in the clinical treatment of glaucoma. 18 The results of this study showed that the EDV and PSV of the two groups were significantly increased after treatment, and the RI was significantly decreased, with more significant changes in the observation group, suggesting the treatment of open-angle glaucoma with latanoprost combined with nimodipine could more significantly improve the ocular hemodynamic indicators of patients than latanoprost monotherapy. In addition, the 24-hour peak intraocular pressure is an important basis for the diagnosis of glaucoma.…”

Section: Discussionmentioning

confidence: 65%

Efficacy of Nimodipine Combined with Latanoprost in Treating Open-Angle Glaucoma and Its Influence on Ocular Hemodynamics and Visual Field Defects

Duan¹,

Liu²

2022

DDDT

View full text Add to dashboard Cite

“…Randomized controlled trials (RCTs), such as APOLLO, JUPITER, LUNAR, VOYAGER, and CONSTELLATION, as well as a pooled study conducted by Weinreb et al, have assessed the IOP-reduction effect of LBN in patients with open-angle glaucoma (OAG) and ocular hypertension (OHT) [ 9 , 10 , 11 , 12 , 13 , 14 ]. Since the approval of LBN, retrospective studies (e.g., chart reviews) regarding its IOP-lowering effect in the real-world setting have been performed [ 15 , 16 , 17 ]. To ensure a complete understanding of LBN 0.024%, we investigated its efficacy in decreasing IOP in both the RCTs and retrospective studies.…”

Section: Introductionmentioning

confidence: 99%

Latanoprostene Bunod 0.024% in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: A Meta-Analysis

Chen

Hung

et al. 2022

JCM

View full text Add to dashboard Cite

Latanoprostene bunod (LBN) 0.024%, a newly approved glaucoma eye drop, is metabolized into latanoprost acid and a nitric oxide (NO)-donating moiety, thus increasing the outflow of aqueous humor through the uveoscleral and trabecular routes, respectively. This study aimed to evaluate the intraocular pressure (IOP)-lowering effect of LBN among patients with open-angle glaucoma (OAG) and ocular hypertension (OHT). The effectiveness of LBN was also compared with timolol maleate 0.5% and latanoprost 0.005%. We searched PubMed and Embase between 1 January 2010, and 31 March 2022 and adopted only peer-reviewed clinical studies in our meta-analysis. A total of nine studies (2389 patients with OAG or OHT) assessing the IOP-reduction effect of LBN were included. Standardized mean differences (SMDs) of IOP between post-treatment time points (2 weeks, 6 weeks, 3 months, 6 months, 9 months, and 12 months) and baseline were calculated. The pooled analysis according to each time point revealed a significant IOP drop after LBN treatment (all p values for SMD < 0.05). In addition, LBN revealed a significantly stronger efficacy in decreasing IOP than timolol maleate 0.5% and latanoprost 0.005% during the follow-up period of three months. No serious side effects of LBN 0.024% were reported. Our study concluded that LBN could achieve good performance for IOP reduction in patients with OAG and OHT. The safety was favorable with no severe side effects.

show abstract

Comparative evaluation of Latanoprostene Bunod, Timolol Maleate, and latanoprost Ophthalmic Solutions to assess their safety and efficacy in lowering intraocular pressure for the management of Open-Angle Glaucoma

Cited by 10 publications

References 19 publications

Two-Year Experience With Latanoprostene Bunod in Clinical Practice

Two-Year Experience With Latanoprostene Bunod in Clinical Practice

Efficacy of Nimodipine Combined with Latanoprost in Treating Open-Angle Glaucoma and Its Influence on Ocular Hemodynamics and Visual Field Defects

Latanoprostene Bunod 0.024% in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: A Meta-Analysis

Contact Info

Product

Resources

About